Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

The stock's fall snapped a two-day winning streak.

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday? Major stock indices have completed their recovery following Monday's sharp drop, buoyed ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie (NYSE:ABBV – Get Free Report) had its target price hoisted by Morgan Stanley from $224.00 to $239.00 in a report ...

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...